255 related articles for article (PubMed ID: 32909680)
1. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
Reifsnider OS; Kansal AR; Franke J; Lee J; George JT; Brueckmann M; Kaspers S; Brand SB; Ustyugova A; Linden S; Stargardter M; Hau N
ESC Heart Fail; 2020 Dec; 7(6):3910-3918. PubMed ID: 32909680
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Kaku K; Haneda M; Sakamaki H; Yasui A; Murata T; Ustyugova A; Chin R; Hirase T; Shibahara T; Hayashi N; Kansal A; Kaspers S; Okamura T
Clin Ther; 2019 Oct; 41(10):2021-2040.e11. PubMed ID: 31561882
[TBL] [Abstract][Full Text] [Related]
6. A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
Tafazzoli A; Reifsnider OS; Bellanca L; Ishak J; Carrasco M; Rakonczai P; Stargardter M; Linden S
Eur J Health Econ; 2023 Dec; 24(9):1441-1454. PubMed ID: 36463524
[TBL] [Abstract][Full Text] [Related]
7. Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
Kolovos S; Bellanca L; Groyer H; Rosano GMC; Solé A; Gaultney J; Linden S
ESC Heart Fail; 2023 Dec; 10(6):3385-3397. PubMed ID: 37670496
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
Ramos M; Foos V; Ustyugova A; Hau N; Gandhi P; Lamotte M
Diabetes Ther; 2019 Dec; 10(6):2153-2167. PubMed ID: 31602601
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.
Hallinen T; Kivelä S; Soini E; Harjola VP; Pesonen M
Clinicoecon Outcomes Res; 2023; 15():1-13. PubMed ID: 36636485
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
Reifsnider OS; Pimple P; Brand S; Bergrath Washington E; Shetty S; Desai NR
Diabetes Obes Metab; 2022 Apr; 24(4):652-661. PubMed ID: 34910356
[TBL] [Abstract][Full Text] [Related]
12. Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE
Fauchier L; Lamblin N; Tardu J; Bellier L; Groyer H; Ittah D; Chollet J; Linden S; Levy P
Pharmacoecon Open; 2024 Jan; 8(1):19-30. PubMed ID: 37606866
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
Ong SC; Low JZ; Linden S
Front Pharmacol; 2023; 14():1195124. PubMed ID: 37342587
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
Ramos M; Men P; Wang X; Ustyugova A; Lamotte M
Cost Eff Resour Alloc; 2021 Aug; 19(1):46. PubMed ID: 34348729
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom.
Ramos M; Gerlier L; Uster A; Muttram L; Frankel AH; Lamotte M
J Med Econ; 2024; 27(1):777-785. PubMed ID: 38758099
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Nguyen E; Coleman CI; Nair S; Weeda ER
J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]